FRANKLIN DEDOMINICIS: Open Payments
NPI 1871031492 · HAMDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,824 in 136 payments from 18 companies in 2025. Trend: 2023 $2,031 · 2024 $2,117 · 2025 $2,824
Food & beverage: $2,824
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 28 | $693 |
| ABBVIE INC. | 37 | $553 |
| Otsuka America Pharmaceutical, Inc. | 18 | $437 |
| GlaxoSmithKline, LLC. | 16 | $299 |
| Novo Nordisk Inc | 7 | $183 |
| Lundbeck LLC | 6 | $134 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $112 |
| Axsome Therapeutics, Inc. | 3 | $89 |
| Amgen Inc. | 3 | $71 |
| Exact Sciences Corporation | 2 | $42 |
Products named: REXULTI, VRAYLAR, BREZTRI, FARXIGA, TRELEGY ELLIPTA, NUCALA, XIFAXAN, Auvelity.
Industry payments across CT — which companies pay providers there.
